Appointment of Geeta Gopalan as a NED
20 December 2022
Dechra® Pharmaceuticals PLC
(Dechra, the Company or the Group)
Appointment of Geeta Gopalan as Non-Executive Director
Dechra is pleased to announce that, with effect from 1 January 2023, Geeta Gopalan will be appointed as a Non-Executive Director of the Company. Geeta will be a member of the Group's Audit, Remuneration and Nomination Committees with the intention that she will be appointed as Chair of the Remuneration Committee from 1 March 2023. Ishbel Macpherson will remain as a member of the Remuneration Committee until 30 June 2023 to enable a smooth handover and will then retire as a Non-Executive Director on 30 June 2023.
Geeta has a breadth of Non-Executive Director experience as well as chairing risk, audit and remuneration committees since 2017. Geeta is currently a Non-Executive Director of Virgin Money UK plc where she is a member of the Remuneration Committee and the Chair of the Risk Committee and Senior Independent Director and Chair of the Audit Committee of Funding Circle Holdings Plc. Previously, she was a Non-Executive Director and Chair of the Remuneration Committee of Ultra Electronic Holdings Plc, and a member of the Remuneration Committee of VocaLink. In addition, Geeta also served as a Non-Executive Director and Chair of the Risk Committee at Wizink Bank SA.
She has over 25 years of experience of financial services and retail banking, particularly payments and digital innovation. She was formerly Executive Chair of Monitise Europe, and Vice Chair of the Big Lottery Fund England. Prior to these roles, Geeta was Director of Payment Services with HBOS plc and previously Managing Director, UK Retail Bank and Business Development Head EMEA at Citigroup.
Geeta is a Chartered Accountant and Trustee of the Old Vic Theatre Trust 2000.
There are no other disclosures to be made in respect of Geeta Gopalan, pursuant to Listing Rule 9.6.13R.
Commenting on the appointment Alison Platt, Chair of Dechra Pharmaceuticals PLC said:
"On behalf of the Board and all stakeholders I am delighted to welcome Geeta to Dechra. She brings significant capabilities and experience both in Executive and Non-Executive roles, which will further strengthen the Board and provide continuity during the next phase of Dechra's growth and development ."
|
Enquiries to: |
|
Dechra Pharmaceuticals PLC |
|
Ian Page, Chief Executive Officer |
|
Office: +44 (0) 1606 814 730 |
|
e-mail: corporate.enquiries@dechra.com |
|
|
|
TooleyStreet Communications Ltd |
|
Fiona Tooley, Director Mobile: +44 (0) 7785 703 523 e-mail: fiona@tooleystreet.com |
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.
For more information please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 7 hours ago Luceco
- 8 hours ago Helios Towers
- 8 hours ago Wise Class A
- 8 hours ago EDX Medical Group Plc
- 8 hours ago Naked Wines